GRAB YOUR SEATS!!!Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

Opportunity ID: 322578 Opportunity Number: CDC-RFA-PS20-2009 Opportunity Title: Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments Opportunity Category: Discretionary Opportunity Category Explanation: Funding Instrument Type: Cooperative Agreement Category of Funding Activity: Health Category Explanation: CFDA Number(s): 93.270 Eligible Applicants: State governments County governments City or township governments Special district governments Additional Information on Eligibility: State governments or their bona fide agents (includes the District of Columbia) Local governments or their bona fide agents Local government jurisdictions are restricted to those with a metropolitan statistical area (MSAs) population > 6 million based on 2018 U.S. Census data population estimates (New York-Newark-Jersey City, NY-NJ-PA; Los Angeles-Long Beach-Anaheim, CA; Chicago-Naperville-Elgin, IL-IN-WI; Dallas-Fort Worth-Arlington, TX; Houston-The Woodlands-Sugar Land, TX; Miami-Fort Lauderdale-West Palm Beach, FL; and Philadelphia-Camden-Wilmington, PA-NJ-DE-MD metro areas) PENDING APPROVAL OF LIMITED COMPETITION JUSTIFICATION Agency Code: HHS-CDC-NCHHSTP Agency Name: Department of Health and Human Services Centers for Disease Control - NCHHSTP Posted Date: Nov 18, 2019 Last Updated Date: Nov 18, 2019 Estimated Synopsis Post Date: Jan 06, 2020 Fiscal Year: 2020 Award Ceiling: $0 Award Floor: $0 Estimated Total Program Funding: $91,350,000 Expected Number of Awards: 58 Description: This notice of funding Opportunity (NOFO) supports integrated viral hepatitis surveillance and prevention programs in states and large cities in the United States. Key strategies include viral hepatitis outbreak planning and response; and surveillance for acute hepatitis A, B and C, and chronic hepatitis C. Applicants should develop a jurisdictional viral hepatitis elimination plan, promote comprehensive hepatitis B and C reporting, improve Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) testing policies, and increase healthcare providers trained to treat hepatitis B and C. Contingent on funding, the following activities can be supported: surveillance for chronic hepatitis B and perinatal hepatitis C; increased hepatitis B and C testing and referral to care in high-impact settings {syringe services programs (SSPs), substance abuse treatment centers, correctional facilities, emergency departments and sexually transmitted disease clinics; and increased access to services preventing viral hepatitis and other bloodborne infections among persons who inject drugs (PWID)}. Contingent on funding, an optional component will support improved access to prevention, diagnosis, and treatment of HBV, HCV, HIV among PWID in jurisdictions disproportionately affected by high-risk drug use. Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk. Version: 1

Published at: November 18, 2019 at 08:45PM
View on Grants.gov